Aperture Bio provides a rapid, ultra-sensitive solution to quantify how, why and when drugs fail.
Aperture bio has raised $150K in total funding. The most recent round was Pre-Seed. The last funding was announced in October 2023.
Aperture bio's investors include Techstars, Merck Digital Sciences Studio.
Aperture bio is headquartered in Allston, United States.
Aperture Bio provides a rapid, ultra-sensitive solution to quantify how, why and when drugs fail.
Aperture bio is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aperture bio — Funding & Investors." VCBacked, October 1, 2023, https://www.vcbacked.co/company/aperture-bio. Accessed August 16, 2026.
VCBacked. (2023). Aperture bio — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/aperture-bio
{{cite web |title=Aperture bio — Funding & Investors |url=https://www.vcbacked.co/company/aperture-bio |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated